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Abstract
Forty-two cell lines recapitulating mammary carcinoma heteroge-
neity were profiled for all-trans retinoic acid (ATRA) sensitivity.
Luminal and ER+ (estrogen-receptor-positive) cell lines are gener-
ally sensitive to ATRA, while refractoriness/low sensitivity is associ-
ated with a Basal phenotype and HER2 positivity. Indeed, only 2
Basal cell lines (MDA-MB157 and HCC-1599) are highly sensitive to
the retinoid. Sensitivity of HCC-1599 cells is confirmed in xeno-
transplanted mice. Short-term tissue-slice cultures of surgical
samples validate the cell-line results and support the concept that
a high proportion of Luminal/ER+ carcinomas are ATRA sensitive,
while triple-negative (Basal) and HER2-positive tumors tend to be
retinoid resistant. Pathway-oriented analysis of the constitutive
gene-expression profiles in the cell lines identifies RARa as the
member of the retinoid pathway directly associated with a Luminal
phenotype, estrogen positivity and ATRA sensitivity. RARa3 is the
major transcript in ATRA-sensitive cells and tumors. Studies in
selected cell lines with agonists/antagonists confirm that RARa is
the principal mediator of ATRA responsiveness. RARa over-
expression sensitizes retinoid-resistant MDA-MB453 cells to ATRA
anti-proliferative action. Conversely, silencing of RARa in retinoid-
sensitive SKBR3 cells abrogates ATRA responsiveness. All this is
paralleled by similar effects on ATRA-dependent inhibition of cell
motility, indicating that RARa may mediate also ATRA anti-
metastatic effects. We define gene sets of predictive potential
which are associated with ATRA sensitivity in breast cancer cell
lines and validate them in short-term tissue cultures of Luminal/
ER+ and triple-negative tumors. In these last models, we determine
the perturbations in the transcriptomic profiles afforded by ATRA.
The study provides fundamental information for the development
of retinoid-based therapeutic strategies aimed at the stratified
treatment of breast cancer subtypes.
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Introduction
ATRA (all-trans retinoic acid) is used in the management of acute
promyelocytic leukemia (Tallman et al, 1997; Lo-Coco et al, 2013),
and the retinoid holds promise for the treatment of solid tumors like
breast cancer (Garattini et al, 2014). The mechanisms underlying
ATRA anti-tumor activity are unique, as the compound is endowed
with anti-proliferative and cyto-differentiating activities, while it is
only a weak cytotoxic agent (Garattini et al, 2007a,b). The retinoid
pathway centers on ligand-dependent transcription factors belong-
ing to the family of steroid nuclear receptors along with ERs/PRs
(estrogen/progesterone receptors) and PPARs (peroxisome prolifera-
tor-activated receptors) (Chambon, 1996; Mark et al, 2009). Six reti-
noid receptors are known, that is RARa/b/c and RXRa/b/c. Each
RAR and RXR isoform is encoded by a distinct gene which is tran-
scribed into splicing variants (Garattini et al, 2014). The active
receptors consist of RXR-RAR heterodimers or RXR-RXR homo-
dimers. While the RXR-RXR homodimers are the target of 9-cis reti-
noic acid and synthetic rexinoids, which are also promising agents
in the chemoprevention of mammary tumors (Wu et al, 2002; Kong
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et al, 2005; Kim et al, 2006; Abba et al, 2008; Uray & Brown, 2011),
the RXR-RAR heterodimers are the classic mediators of ATRA activ-
ity. In the RXR-RAR complexes, RARs act as the ligand-binding
moiety. ATRA is a pan-RAR agonist, binding RARa/b/c with the
same affinity (Di Lorenzo et al, 1993; Gianni et al, 1996) and it also
binds and activates PPARb/d (Shaw et al, 2003; Berry & Noy, 2007;
Schug et al, 2007). In mammary tumors, ATRA-liganded RXR-RARs
are purported to mediate growth inhibition, whereas RXR-PPARb/d
induces proliferation (Noy, 2010). ATRA is transported to the
nucleus by CRABP1 and CRABP2 (cytosolic retinoic acid-binding
proteins-1/-2) as well as FABP5 (fatty acid-binding protein-5)
(Schug et al, 2007). While CRABP2 delivers ATRA to RXR-RARs,
FABP5 targets RXR-PPARb/d (Schug et al, 2007).
Breast cancer is a heterogeneous disease classified into subtypes
according to the gene-expression profiles (Sorlie et al, 2003; Guedj
et al, 2012). A rational use of ATRA and retinoids in breast cancer
requires the definition of the sensitive subtypes (Garattini et al,
2014). Identification of the molecular determinants underlying reti-
noid sensitivity is another priority. The availability of representative
cell lines characterized for the gene-expression profiles is a unique
opportunity to establish the cellular/molecular determinants of reti-
noid sensitivity in mammary tumors. In this study, we tested the
susceptibility of a large panel of breast cancer cell lines to ATRA,
subsequently validating and extending the results in short-term
tissue cultures of primary tumors. We identify RARa as the main
retinoid receptor variant mediating the anti-tumor activity of the
retinoid. In addition, we define gene sets, which are associated with
ATRA sensitivity, and are of predictive potential. Finally, we deter-
mine the perturbations of the transcriptome afforded by ATRA in
LuminalA/B and triple-negative (TN) tumors.
Results
Sensitivity of breast cancer cell lines to retinoids
To define ATRA sensitivity, we selected 42 cell lines representative
of breast cancer heterogeneity (Supplementary Table S1) and char-
acterized for ER, PR, and HER2 status as well as the Luminal or
Basal phenotype according to PAM50 (Tibshirani et al, 2002; Parker
et al, 2009) (Supplementary Fig S1). The concentration-dependent
growth-inhibitory effects of ATRA (0.001–10 lM) at 3, 6, and
9 days were evaluated, as exemplified by the SKBR3, HCC-1954,
and MDA-MB436 cell lines showing different ATRA sensitivity
(Fig 1A). The doubling time of each cell line and a number of other
parameters associated with ATRA-dependent growth inhibition
were determined (Supplementary Table S2). All these parameters
are the basis for the calculation of the ATRA score, a new and
robust index defining cell sensitivity to the growth-inhibitory action
of ATRA (Supplementary Methods). The higher the ATRA score is,
the higher is ATRA sensitivity. Development of this new index was
necessary, since determination of standard IC50 values for the defi-
nition of sensitivity to the anti-proliferative effect of ATRA was
deemed inadequate for at least two reasons. The IC50 is routinely
and successfully used to assess cell sensitivity to cytotoxic
compounds, while ATRA is predominantly a growth inhibitory and
cyto-differentiating agent and it is largely devoid of a direct cyto-
toxic action (Garattini et al, 2007b, 2014). Given the slow kinetics
of the response to the retinoid, we calculated the ATRA score
between days 3 and 6.
The ATRA score provides a continuous series of values across
our panel of cell lines and identifies four separable groups (A–D,
Fig 1B). The subsets with high and intermediate sensitivity (groups
A and B) are enriched for cells with Luminal and ER+ phenotypes.
Indeed, 14/16 of the cell lines in combined groups A and B are
Luminal and 11/16 are ER+. Interestingly, SKBR3 and AU565,
representing a subgroup of HER2+ tumors which is predicted to be
sensitive to ATRA due to co-amplification of the RARA and ERBB2
loci (Paroni et al, 2012), are the only ER/HER2+ cell lines present
in group A. Similarly, HCC-1599 and MDA-MB157 are the only
Basal cell lines in groups A and B, respectively. Group C clusters
the cell lines characterized by low sensitivity to ATRA. In this
group, the proportion of Luminal (6/14) and ER+ (3/14) cell lines
is reduced. Group D concentrates ATRA-resistant lines, the majority
of which is Basal (10/12). Thus, the ATRA scores indicate that a
Luminal phenotype and ER expression are major determinants of
cell sensitivity to the anti-proliferative action of ATRA. In contrast,
a Basal phenotype represents a negative factor. Indeed, the propor-
tion of Basal cell lines increases as the ATRA score decreases if our
panel is divided in tertiles (T1 = 2/14; T2 = 6/14; T3 = 12/14)
(Fig 1B).
Being one of the two Basal lines with a high ATRA score and one
of the rare breast cancer lines transplantable in mice (Zhang et al,
2013), HCC-1599 represents a unique model to validate our ATRA-
sensitivity data in vivo. Thus, SCID mice bearing subcutaneous HCC-
1599 xenografts were treated with ATRA (15 and 7.5 mg/kg) or
vehicle on a daily basis for 3 weeks, and tumor growth was
followed. A time- and dose-dependent reduction in the tumor
volume is evident in mice treated with ATRA (Fig 2A). With the
highest dose of ATRA, the effect is already significant after 17 days
and is maintained for at least 10 days after treatment discontinua-
tion. The total body weight of mice is not different in the experimen-
tal groups, demonstrating lack of ATRA-dependent toxicity
(Supplementary Fig S2). The results were validated by MRI analyses
performed at 24 days (Fig 2B). Taken together, the results support
the in vivo relevance of the cell-line studies.
Short-term cultures of mammary tumors: anti-proliferative
responses to ATRA
To confirm the results obtained with the cell lines, we used short-
term cultures of mammary tumors (van der Kuip et al, 2006)
derived from diagnostic Tru-cut procedures of 45 patients (Supple-
mentary Table S3). To assess the anti-proliferative activity of
ATRA, tissue slices were challenged with vehicle or the retinoid
for 48 h, the maximal time interval maintaining tumor cell viabil-
ity in basal culture conditions. The growth of tumor cells was eval-
uated with Ki67 (Fig 3A and B), which is an established biomarker
of cell division and it is routinely used in the clinics to assess the
proliferation rate of breast cancer. Ki67 is rapidly down-regulated
by a number of anti-proliferative agents in short-term tissue
cultures of primary tumors (Alagesan et al, 2015). Rapid down-
regulation of the biomarker is of the outmost importance, given
the relatively short exposure times to ATRA that our tissue culture
model allows and the slow anti-proliferative effect exerted by the
retinoid.
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The cases used in our study are classified according to standard
clinical criteria and consist of 17 Luminal-A, 14 Luminal-B, 7
HER2+, and 7 TN (triple-negative) tumors. All the Luminal-A and
Luminal-B tumors are characterized by > 70% ER+ cells. ATRA
reduces the proliferation of 11 Luminal-A and 10 Luminal-B tumors
(Fig 3B). Except for growth inhibition of the two cases character-
ized by co-amplification of the ERBB2 and RARA loci (patients 26
and 67) (Paroni et al, 2012), the retinoid exerts no significant effect
on HER2+ tumors. Only one of the TN or Basal cancers responds
to ATRA. The data are consistent with the cell-line results and
confirm that ATRA sensitivity is frequent in Luminal and ER+
tumors.
Associations between the cellular phenotype and genes of the
retinoid pathway
Known members of the retinoid pathway are likely to be major
mediators of ATRA anti-tumor activity. Given the respective associa-
tions with ATRA sensitivity and refractoriness observed in cell lines
and primary tumors, we evaluated whether the Luminal and Basal
A
B
Figure 1. Profiling of the breast cancer cell-line panel according to ATRA sensitivity.
A panel of 42 breast cancer cell lines was challenged with increasing concentrations of ATRA (11 nM–10 lM) for 3, 6, and 9 days, and cell growth was determined.
A The graphs show the growth-inhibitory effect exerted by the indicated concentrations of ATRA in SKBR3, HCC-1954, and MDA-MB436 cells which are representative of
lines characterized by a high, intermediate and low ATRA score, respectively. Each point is the mean  SD of three replicate cultures. **Significantly lower than the
corresponding vehicle-treated group (P-value < 0.01, Student’s t-test).
B Cell lines are ranked in ascending order according to the ATRA score. The plot distinguishes four separate groups of cell lines (D–A) with increasing ATRA scores, as
indicated by the colored scale on the right. The cell lines are also grouped in tertiles, T1–T3, according to an ascending ATRA score. Each calculated value is
representative of at least two independent experiments.
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phenotype as well as ER and HER2 positivity influence the expres-
sion of retinoid receptors/binding proteins. Both the microarray and
the RNA-seq data associated with our panel of cell lines indicate that
the average levels of RARa, RXRa, and CRABP2 are significantly
higher in Luminal than Basal cells (Fig 4), while FABP5 shows an
opposite pattern. Thus, Luminal cells are predisposed to activate
CRABP2/RARa upon ATRA challenge. In the context of Luminal cell
lines, these mRNAs show the same expression profile in ER+ rela-
tive to ER cells. In the HER2+ cellular context (SKBR3, AU565, and
UACC812 cell lines), the data confirm that RARA co-amplification
results in high levels of RARa (Paroni et al, 2012).
To evaluate whether the expression patterns of retinoid receptors/
binding proteins in cell lines recapitulate the situation in mammary
tumors, we analyzed the TCGA RNA-seq dataset consisting of
over 1,000 breast tumors classified into Luminal-A, Luminal-B,
HER2-like, Normal-like and Basal according to PAM50. Consistent
with the cell-line data, Basal tumors synthesize the smallest
amounts of RARa, RXRa, and RXRc and the highest levels of FABP5
(Fig 5A and B). The analysis unmasks associations which are not
evident in cell lines, that is, direct correlations between RARb/
RXRb/CRABP1/PPARb/d expression and the Basal phenotype. Given
the poor responsiveness of Basal cell lines to the retinoid (Fig 1B),
these results support the notion that FABP5 and PPARb/d are nega-
tive determinants of ATRA sensitivity (Balmer & Blomhoff, 2002;
Kannan-Thulasiraman et al, 2010). As for RARb, its expression does
not seem to be important for ATRA anti-tumor activity in breast
cancer (Connolly et al, 2013). In conclusion, our data demonstrate
that RARa is the only receptor with a high level of expression in the
cellular phenotypes predicted to be responsive to ATRA.
Direct associations between RARa and ATRA sensitivity
After grouping all the cell lines in ascending tertiles (T3 to T1) accord-
ing to the ATRA score, we looked for associations between retinoid
receptors/binding proteins and ATRA sensitivity. According to both
the microarray and RNA-seq results, the average amounts of RARa
are significantly higher in T1 (ATRA sensitive) than T3 (ATRA resis-
tant) cell lines (Fig 6A). No difference in the amounts of PPARb/d
(Fig 6A), RARb, RARc, RXRa, RXRb, RXRc, CRABP2, and FABP5
(Supplementary Fig S3) is evident. RARa is also significantly over-
expressed in the T1 group, if the analysis of the microarray data is
limited to the 22 Luminal cell lines and the trend is confirmed by
RNA-seq, although the results do not reach statistical significance. In
the microarray data, T1 cells express larger amounts of PPARb/d
(Fig 6A) than the T3 counterparts, after restriction to the Basal subset
(20 cell lines). Thus, RARa is likely to be a determinant of ATRA sensi-
tivity in both the total and Luminal fraction of cell lines, while
PPARb/dmay represent a positive factor in Basal cell lines.
The complement of RAR splicing variants in cell lines and primary
tumors: RARa3 as the major determinant of ATRA sensitivity
RARa (RARa1-4), RARb (RARb1-2-5), and RARc (RARc1-5) splicing
variants are known (Supplementary Fig S4). Quantitative PCR was
used to determine basal expression of these variants in our panel of
cell lines. In the majority (40/42) of the cell lines (Supplementary
Fig S5A), RARa3 is the most highly expressed RARa mRNA, being
at least one order of magnitude more abundant than RARa2 and
RARa1. Extremely low levels of RARa4 are generally observed. Only
RARa3 and RARa4 show significant co-regulation across the panel
(Supplementary Fig S5B), consistent with transcriptional control by
the same promoter. Luminal cells contain significantly larger
amounts of RARa3, RARa1, and RARa4 mRNAs than the Basal
counterparts (Table 1). Higher levels of the same transcripts are also
associated with ER positivity, although statistical significance is not
reached if analysis is restricted to the Luminal cell lines. If associa-
tions between RARa variants and ATRA sensitivity are searched for,
significant over-expression of RARa3 in T1 relative to T3 cell lines is
evident (Fig 6B). A similar, though less significant, association is
A
B
Figure 2. ATRA-dependent anti-tumor activity in HCC-1599-derived
xenografts in vivo.
SCID mice were xenografted subcutaneously with 10 × 106 HCC-1599 cells on
both sides. One week after transplantation 10 animals/experimental group were
treated intraperitoneally with vehicle (DMSO) or two doses of ATRA (7.5 and
15.0 mg/kg) once/day, 5 days a week for a total of 24 days. At the end of this
period, treatment was discontinued until sacrifice.
A The size of the tumors was determined with a caliper and the volume plotted.
Each point is the mean  SE of 20 tumors. *Significantly lower than the
corresponding vehicle-treated group (P-value < 0.05, Student’s t-test).
**Significantly lower than the corresponding vehicle-treated group
(P-value < 0.01, Student’s t-test).
B Magnetic resonance imaging (MRI) analysis was performed on five animals/
experimental group on day 24. The picture shows representative 2D images
of tumor sections from one animal treated with vehicle and one animal
treated with 15.0 mg/kg ATRA. The bar graph shows the volume of the
tumors calculated after 3D reconstruction of the MRI images. Each point is
the mean  SE of five tumors. The P-value of the comparisons of ATRA
versus vehicle is shown.
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Figure 3. ATRA-dependent anti-tumor activity in short-term cultures of primary breast tumors.
Tissue slices deriving from surgical specimens were challenged with vehicle (DMSO) or ATRA (0.1 lM) for 48 h.
A The panel illustrates examples of the immuno-histochemical data obtained in four representative cases: (i) Luminal-A (Lum A); (ii) Luminal-B (Lum B); (iii) Her2+ with
RARA coamplification (Her2+/RARA+) and (iv) triple negative (TN).
B The percentage of Ki67-positive tumor cells in the 45 samples considered are illustrated by the bar graphs. Each value represents the mean  SE of at least five
separate fields for each experimental sample. *Significantly lower than the corresponding vehicle-treated control (P-value < 0.05, Student’s t-test). **Significantly
lower than the corresponding vehicle-treated control (P-value < 0.01, Student’s t-test).
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Figure 4. Associations between components of the retinoid signaling pathway and the phenotype in breast cancer cell lines.
The figure illustrates the associations between the indicated retinoid receptors/binding proteins and the Luminal versus Basal phenotype (left panels), ER positivity versus
ER negativity (middle panels) as well as HER2 positivity versus HER2 negativity (right panels). The gene-expression microarray and RNA-seq data refer to 42 and 40
breast cancer cell lines, respectively. The P-values of the indicated comparisons after Student’s t-test are shown in red. L (red) = Luminal cell lines; B (blue) = Basal cell lines;
ER+ (red) = ER-positive cell lines; ER (red) = ER-negative cell lines; ER (blue) = ER-negative Luminal cell lines; H+ (red) = HER2-positive cell lines; H (red) = HER2-negative
cell lines; H+ (blue) = HER2-positive Luminal cell lines; H (blue) = HER2-negative Luminal cell lines. fpkm = fragments per kilobase of exon per million fragments mapped.
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Figure 5. Associations between components of the retinoid pathway and breast cancer phenotype.
Associations between the expression of the indicated members of the retinoid pathway in the TCGA gene-expression database are shown. Mammary tumors are classified
into Luminal-A, Luminal-B, HER2-like, Normal-like, and Basal according to the PAM50 fingerprint. The average expression levels and the corresponding SD values of the
indicated members of the retinoid pathway are shown by the upper box plots. For each member of the retinoid pathway, significant differences between the indicated groups
of tumors are shown in the lower table. Significant P-values for the indicated comparisons (Student’s t-test) are shown in red.
Figure 6. Associations between components of the retinoid signaling pathway and ATRA sensitivity.
A The gene-expression microarray and RNA-seq data associated with 40 of the breast cancer cell lines were used for the analyses. The panels illustrate the associations
of RARa and PPARb/d with ATRA sensitivity. The left panels show the basal average levels of the indicated transcript in the cell lines belonging to the T1 and T3
groups (13 cell lines in each of the T1 and T3 groups) defined by ascending ATRA scores. The intermediate and right panels indicate the same results after stratification
for the Luminal (microarray and RNA-seq data = 7 cell lines in each of the T1 and T3 groups) and the Basal (microarray and RNA-seq data = 7 cell lines in each of the
T1 and T3 groups) phenotype, respectively. fpkm = fragments per kilobase of exon per million fragments mapped.
B The basal expression levels of the indicated RAR-isoform variants were determined with the use of specific Taqman assays. The results are associated with ATRA
sensitivity before (TOTAL) and after stratification of the cell lines for the Luminal and Basal phenotype as in (A).
Data information: Significant P-values (Student’s t-test) are indicated in red.
▸
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Figure 6.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 7 | 2015
Floriana Centritto et al Retinoid sensitivity in breast cancer EMBO Molecular Medicine
957
observed with RARa1 and RARa4. After stratification for the
Luminal/Basal phenotype, the association between RARa3 and
ATRA sensitivity is maintained solely in Luminal cells.
We determined RARb1 expression and combined expression of
RARb2 and 5, as the last two variants code for the same protein.
RARb1 is the most abundant species, although the transcript is
detectable only in 15 of 42 cell lines (Supplementary Fig S6A).
Despite regulation by distinct promoters, RARb1 and RARb2/5 are
always co-expressed (Supplementary Fig S6B). Both RARb1 and
RARb2/5 are over-expressed in Basal relative to Luminal cells. The
same is true in ER versus ER+ cell lines, even if the analysis is
restricted to the Luminal/ER group (Supplementary Fig S6C).
Regarding possible associations with ATRA sensitivity, no signifi-
cant difference in the levels of RARb1 or RARb2/5 between the T1
and T3 cell lines is evident before or after stratification for the
Luminal/Basal phenotype (Fig 6B).
As for RARc, we focused our attention on RARc1-3, which are
predicted to code for active transcription factors. The order of
expression for the RARc forms is RARc1 >> RARc2 > RARc3
(Supplementary Fig S7A). Consistent with regulation by the same
promoter, only the RARc2/RARc3 couple is characterized by co-
regulation across all the cell lines (Supplementary Fig S7B). As the
RARb variants, RARc2 and RARc3 show a direct association with
the Basal and ER phenotypes (Supplementary Fig S7C), while
only RARc3 is significantly higher in HER2 than HER2+ cells. In
addition, RARc2 and RARc3 tend to be over-expressed in the T3
relative to the T1 group (Fig 6B), supporting the idea that they
represent negative factors in terms of ATRA sensitivity (Bosch
et al, 2012).
Taken together, the results point to RARa3 as the principal
element of the retinoid pathway mediating the anti-proliferative
responses of Luminal cells to ATRA.
RARa3 as a major player of ATRA sensitivity in primary tumors
The profiles of expression of the RAR splicing variants were
defined in the primary tumors used to evaluate ATRA sensitivity
(see Fig 3). In all the specimens considered, RARa3 and RARa2
are the most abundant RARa mRNAs and have a similar level of
expression (Fig 7A), which is different from what is observed in
the cell lines. Across all the samples, RARb1 is more abundant
than RARb2, although RARb1 levels are at least one order of
magnitude lower than the RARa3/RARa2 counterparts. In the case
of the RARc variants, RARc1 and RARc2 show intermediate levels
of expression relative to RARa3/RARa2 and RARb1/RARb2. RARc2
in primary tumors is more abundant than expected from the cell-
line results, while RARc3 is by far the least abundant species. The
expression of RARa3/RARa1, RARa3/RARa2, RARa3/RARa4,
RARa2/RARa4, RARc1/RARc2, RARc1/RARc3, and RARc2/RARc3
across the tumor samples is highly correlated (Supplementary
Fig S8).
As for possible associations between RAR splicing variants and
tumor cell phenotype, in accordance with the cell-line data, the
content of RARa3 is generally higher in Luminal, relative to TN
cancers and HER2+ tumors with no co-amplification of the ERBB2
and RARA loci (Fig 7A). In the case of the RARb variants, expres-
sion is similar in the tissue samples and cell lines, as the average
levels of RARb1 are significantly more abundant in TN (Basal) than
Table 1. Associations between the RARa splicing variants and the phenotype in breast cancer cells.
RARa1 (mean  SE) RARa2 (mean  SE) RARa3 (mean  SE) RARa4 (mean  SE)
Basal cell lines (A) 0.12  0.03 1.11  0.29 6.92  1.23 0.03  0.01
Luminal cell lines (B) 0.34  0.08 0.54  0.16 30.98  10.04 0.09  0.02
t-test A versus B P = 0.01 P = 0.09 P = 0.02 P = 0.01
ER+ cell lines (C) 0.40  0.10 0.64  0.20 39.73  15.39 0.12  0.04
ER cell lines (D) 0.15  0.04 0.90  0.22 9.42  1.83 0.03  0.01
ER Luminal cell lines (E) 0.23  0.14 0.36  0.26 15.68  5.46 0.04  0.02
t-test C versus D P = 0.02 P = 0.39 P = 0.05 P = 0.03
t-test C versus E P = 0.27 P = 0.39 P = 0.15 P = 0.06
t-test D versus E P = 0.47 P = 0.06 P = 0.13 P = 0.38
HER2+ cell lines (F) 0.27  0.11 0.28  0.11 38.69  18.58 0.09  0.04
HER2 cell lines (G) 0.22  0.05 1.02  0.21 11.86  1.92 0.05  0.01
HER2+ Luminal cell lines (H) 0.27  0.12 0.31  0.14 43.54  22.26 0.10  0.05
HER2 Luminal cell lines (I) 0.35  0.11 0.73  0.26 20.35  3.43 0.09  0.02
t-test F versus G P = 0.66 P = 0.003 P = 0.16 P = 0.39
t-test F versus H P = 0.99 P = 0.86 P = 0.86 P = 0.86
t-test F versus I P = 0.58 P = 0.13 P = 0.33 P = 0.97
t-test G versus H P = 0.71 P = 0.006 P = 0.17 P = 0.35
t-test G versus I P = 0.27 P = 0.38 P = 0.04 P = 0.18
t-test H versus I P = 0.60 P = 0.16 P = 0.30 P = 0.86
The table shows the associations between RARa1-4 and the Luminal versus Basal phenotype, ER positivity versus ER negativity, as well as HER2 positivity versus
HER2 negativity. P-values for the indicated comparisons (Student’s t-test) are shown.
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Figure 7. Basal levels of RARa, RARb, and RARc mRNA splicing variants in mammary tumors.
Total RNA was extracted from the tissue slices deriving from the surgical specimens of breast cancer patients used in Fig 3 before any treatment with DMSO or ATRA. RNA was
subjected to RT–PCR analysis to determine the basal expression of the indicated RAR splicing variants.
A Each value represents the mean  SD of two replicate measurements. The table shows the statistical significance of the indicated comparisons. *Significantly
different (P-value < 0.05, Student’s t-test). **Significantly different (P-value < 0.01, Student’s t-test).
B The plots illustrate the average expression levels of the indicated mRNAs (mean  SD of two replicates) in tumor samples classified as ATRA-sensitive (Sens) and
ATRA-resistant (Res) according to the response of Ki67. *Significantly different (P-value < 0.05, Student’s t-test).
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in all the other tumor sub-types (Fig 7A). In terms of possible asso-
ciations between RAR splicing variants and ATRA sensitivity, only
the levels of RARa3 are significantly higher in sensitive than in
refractory tumors (Fig 7B).
In conclusion, the complement of RAR splicing variants in breast
tumors and derived cell lines is not entirely superimposable. Never-
theless, the profiles of RAR splicing variants in our cohort of
mammary tumors support a major role of RARa3 in the anti-tumor
responses to ATRA, which is in line with the conclusions drawn in
cell lines.
RARa protein and ATRA sensitivity in breast cancer cell lines
Given the observed relevance of the RARa3 transcript in our
models, the basal levels of the corresponding RARa protein were
determined in breast cancer cell lines with a specific antibody
(Fig 8A and B). The average levels of RARa are significantly higher
in T1 versus T3 ATRA score groups (Fig 8C), and the same trend is
observed if the analysis is restricted to Luminal cells. Larger
amounts of RARa are also observed in Luminal versus Basal and
ER+ versus ER cell lines. As for possible correlations with the
RARa mRNA variants across the cell lines, the highest R2 values
were calculated for the RARa protein and the RARa3/RARa4
mRNAs (Fig 8D). This indicates that the protein is encoded by either
the RARa3 or the RARa4 transcript. Given the low relative expres-
sion levels of RARa4, we favor RARa3.
Effects of RAR agonists/antagonists in breast cancer cells
The functional role of RARa in the anti-proliferative action of ATRA
was evaluated in Luminal and Basal cell lines with different ATRA
scores and RAR-variant expression profiles (Fig 9) with a pharmaco-
logical approach, using the validated (Supplementary Fig S9)
AM580 RARa agonist (Gianni et al, 1996), the UVI2003 RARb
agonist (Alvarez et al, 2014), and the BMS961 RARAc agonist
(Gianni et al, 1993). The cell lines were challenged with increasing
concentrations of ATRA, AM580, UVI2003, and BMS961 for 3 (data
not shown) and 6 days prior to evaluation of cell growth. In the
ATRA-sensitive Luminal lines, AM580 is the only agonist which
inhibits growth in a dose-dependent manner. In ER+/HER2 HCC-
1428 cells, AM580 is more effective than ATRA, while the opposite
is true in the ER/HER2 EVSAT counterpart. In the remaining
Luminal lines, AM580 and ATRA show similar efficacy. AM580 is
also the sole agonist inhibiting the growth of the retinoid-sensitive
Basal cell lines, HCC-1599, MDA-MB157, and HCC-1954. In these
cellular contexts, no significant difference in the anti-proliferative
activity of AM580 and ATRA is noticeable. AM580, UVI2003,
BMS961, and ATRA are equally ineffective in retinoid-resistant
HCC-38 cells.
To corroborate the results obtained with the RAR agonists, we
evaluated the effects of the RARa antagonist, ER50891 (Kikuchi
et al, 2001; Somenzi et al, 2007), and the RARb/c antagonist,
CD2665 (Szondy et al, 1997), on ATRA-dependent growth inhibition
of HCC-1428 and SKBR3 cells, which are characterized by very high
ATRA scores. To obtain maximal blockade of the two RARs without
off-target effects, cells were treated with 100 nM ATRA and 3 lM of
ER50891 or CD2665, as this concentration of the antagonists
blocks the trans-activating potential of ATRA in a RARa- and
RARb/c-specific fashion, respectively (Supplementary Fig S10). In
HCC-1428 and SKBR3 cells, only ER50891 blocks the anti-prolifera-
tive action of ATRA (Supplementary Fig S11).
RARa and ATRA sensitivity: over-expression and
knock-down studies
To obtain direct proof that the RARa3 protein is mediating the
action of ATRA, we over-expressed it in retinoid-resistant, HER2+/
ER, and Luminal MDA-MB453 cells. Two RARa-over-expressing
(RARA-C5 and RARA-C7), two vector-transfected control (Vect-C1
and Vect-C2) clones, and the parental MDA-MB453 cells (WT) were
used in comparative experiments. WT, Vect-C1, and Vect-C2 express
barely detectable levels of the RARa protein, while large amounts of
the product are synthesized by RARA-C5 and RARA-C7 cells
(Fig 10A). RARA-C5 and RARA-C7 express a transcriptionally active
RARa form, as indicated by ATRA-dependent activation of the
luciferase-based retinoid reporter, DR5-RARE-Luc. Over-expression
of RARa does not exert major effects on the basal growth rate of the
MDA-MB-453 clones (Fig 10B). Upon treatment with increasing
concentrations of ATRA for 3, 6, and 9 days, Vect-C1 and Vect-C2
andWT cells are equally unresponsive to retinoid-dependent growth
inhibition (Fig 10C). In contrast, RARA-C5/RARA-C7 proliferation is
inhibited dose- and time-dependently by ATRA. Thus, stable over-
expression of RARa renders MDA-MB-453 cells sensitive to the reti-
noid with an ~4-fold increase in the calculated ATRA score at
9 days.
In a mirror series of experiments, we knocked down RARa in the
retinoid-sensitive HER2+/ER and Luminal SKBR3 cells by stable
transfection of a RARa1/3-targeting shRNA. The two shRNA-
transfected RARA-sh18 and RARA-sh19 clones express < 10% of the
RARa protein levels in the parental (data not shown) and void
vector-transfected Vect-C6 or Vect-C8 cells (Fig 10D). Transfection of
DR5-RARE-Luc in RARA-sh18 and RARA-sh19 cells demonstrates
inhibition of ATRA-dependent transcriptional activity relative to the
Vect-C6 or Vect-C8 counterparts (Fig 10D). While the shRNA
constructs and void vectors do not alter the basal growth rate
of SKBR3 cells (Fig 10E), RARa knockdown attenuates the
anti-proliferative action of ATRA (Fig 10F). Attenuation is observed
at concentrations of ATRA between 0.001 and 0.1 lM and tends to
be lost at the two highest concentrations considered, where ATRA
exerts off-target effects.
We evaluated whether modulation of RARa has any effect on
ATRA-dependent expression of four direct retinoid target genes.
ATRA-dependent induction of CYP26A1, CYP26B1, BTG2, and
RARRES3 is not observed in Vect-C2 cells (Supplementary Fig
S12A). In contrast, ATRA induces the expression of the first three
transcripts in RARA-C5 cells. Similar differential effects are observed
if the levels of the two retinoid-dependent epithelial differentiation
markers, b-catenin and SMAD3 (Paroni et al, 2012), are measured
in Vect-C1, Vect-C2, RARA-C5, and RARA-C7 cells before and after
treatment with ATRA (Supplementary Fig S12B). Conversely,
ATRA-dependent induction of the CYP26A1, CYP26B1, BTG2, and
RARRES3 mRNAs as well as the b-catenin and SMAD3 proteins
observed in Vect-C8 cells is blocked in RARA-Sh18 cells. Thus, RARa
is the predominant mediator not only of the anti-proliferative, but
also of the transcriptional effects afforded by ATRA in the two breast
cancer cells.
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To determine whether RARa mediates other ATRA-dependent
responses of relevance for the anti-tumor activity of the retinoid,
we measured single-cell random motility, as the process is a deter-
minant of invasive/metastatic behavior and it is inhibited by ATRA
in breast cancer cells (Terao et al, 2011). As expected from the
results in parental lines (data not shown), MDA-MB453-derived
Vect-C1 cells are unresponsive to the anti-motility action of ATRA
(Fig 10G), while SKBR3-derived Vect-C6 cells respond with a
significant reduction in random motility. RARa over-expression
sensitizes RARA-C5 and RARA-C7 cells to ATRA, while RARa
knockdown induces ATRA resistance in RARA-sh18 and RARA-sh19
cells. These data support a key role of RARa in mediating the
anti-metastatic activity of ATRA.
Identification of gene sets associated with ATRA sensitivity
Besides RARa, other gene products are likely to play a role in the
anti-tumor action of ATRA. Thus, we looked for genes whose basal
levels of expression are correlated to the ATRA score across our
panel of cell lines using the microarray/RNA-seq databases and a
regressed Random Forest approach (Supplementary Fig S13). The
goal was the generation of ranked lists of genes associated with
ATRA sensitivity based on the variable importance scores (Supple-
mentary Table S4).
We generated two distinct expression heat-maps of the top 100
RNA-seq (Fig 11, left) and microarray (Fig 11, right) genes associ-
ated with ATRA sensitivity in the two databases. Fourteen of the
genes are common to the microarray and RNA-seq gene sets. This is
a high proportion considering the large difference in the quantifiable
gene products between the two datasets (RNA-seq = 57,789; micro-
array = 15,543). Cluster analysis of both the microarray and
RNA-seq data allows a clear separation of the lines belonging to the
T1 and T3 groups identified by the ATRA score. Although our gene
sets may contain elements specific to Luminal or Basal cell lines, as
indicated by the presence of three PAM50 genes (estrogen receptor
1, ESR1; progesterone receptor, PGR; CXXC finger protein 5,
CXXC5), it must be noticed that they do not simply stratify the cell
lines according to the Luminal or Basal phenotype. To validate the
expression results with an independent assay, we performed quanti-
tative real-time PCR on 14 selected genes. The PCR, microarray, and
RNA-seq results are concordant (Supplementary Fig S14).
By far the highest ranking retinoid nuclear receptor in the list
generated from the microarray data is RARa, standing within the
first 3.6% of the ranked mRNAs. RARa is also highly ranked in the
RNA-seq list (top 16.5%). Some of the 100 top-ranking genes pres-
ent in both lists may be of interest for the anti-tumor action of
ATRA. For instance, CXXC5 is a retinoid-inducible gene (Knappskog
et al, 2011; Astori et al, 2013), and it mediates the proliferative
responses of IGFs and HER2 in breast cancer (Montero et al, 2011,
2013). The ATRA-regulated SYT7 (Synaptotagmin-VII) (Ekici et al,
2008) and VAMP3 (vesicle-associated-membrane protein-3) proteins
control the homeostasis of micro-vesicles, which, in turn, regulate
mammary tumorigenesis (Wright et al, 2009). A splicing variant of
CPE (carboxypeptidase-E) stimulates growth, and it is a biomarker
for mammary tumor metastatic spread (Lee et al, 2011). In IRAK1
(interleukin-1-receptor-associated kinase-1) knockout macrophages,
RARa expression is higher than in the parental counterparts (Maitra
et al, 2009).
The two identified gene sets may be useful for the stratification
of patients who are likely to benefit from retinoid-based therapeutic
approaches. We evaluated whether primary Luminal tumors, which
are generally responsive to the anti-proliferative action of ATRA, are
enriched for elements present in both gene sets (Fig 11, bottom),
comparing the 11 Luminal and 5 TN tumors used to assess the geno-
mic effects of ATRA (see Fig 12). The enrichment (single sample
Gene Set Enrichment Analysis, ssGSEA) of genes whose basal levels
of expression is higher in ATRA-sensitive (T1 group) than in ATRA-
refractory (T3 group) cell lines is significantly higher in Luminal
relative to TN tumors. In contrast, the enrichment of genes whose
basal levels of expression is lower in the T1 than in the T3 group
tends to be lower in Luminal than TN tumors. The two identified
gene sets are the basis for the generation of an optimized gene
signature predictive of ATRA sensitivity.
Transcriptional responses to ATRA in short-term cultures of
mammary tumors
The results obtained in the cell lines and the short-term cultures of
primary tumors support the concept that Luminal and ER+ pheno-
types are positive determinants, while Basal and ER phenotypes
are negative determinants of sensitivity to the anti-proliferative
action of ATRA. To evaluate the transcriptional effects of the
retinoid, we performed microarray gene-expression studies in 16 of
the 45 primary-tumor samples profiled with the Ki67 biomarker (see
Fig 3). The cohort analyzed consisted of 11 Luminal and 5 TN
cases. Microarray data were validated by quantitative PCR on a
selected number of tumors and genes (CYP26A1, CYP26B1,
RARRES3, and BTG2) (Supplementary Fig S15).
Figure 8. RARa protein and ATRA sensitivity in breast cancer cell lines.
Total proteins were extracted from logarithmically growing cell lines and subjected to Western blot analysis.
A The panel illustrates representative Western blots for a number of cell lines. The blots were sequentially developed with RARa-specific and control tubulin antibodies.
The positions of the RARa and tubulin bands (right) along with the position of a relevant molecular weight marker (left) are indicated. To normalize the Western blot
signals in different gels, the same preparation of RARa-transfected COS-7 cell extracts (COS-7) and MCF7 extracts was loaded in each gel. The blots are representative
of at least two independent experiments providing similar results.
B The quantitative results obtained after densitometric analysis of the RARa bands are plotted against the ATRA scores. Cell lines are grouped according to the ATRA
score (A–D groups and T1–T3 tertiles).
C Left: The upper graph indicates the averages expression levels of the RARa protein in T1–T3 cell lines. The middle and lower graphs indicate the average expression
levels after stratification of the cell lines for the Luminal (six cell lines in each of the T1 and T3 groups) and the Basal (six cell lines in each of the T1 and T3 groups)
phenotype, respectively. Right: The levels of the RARa protein in Basal and Luminal cell lines (upper graph), in ER+, ER, and Luminal ER cell lines (middle graph) and
the indicated classes of HER2+ and HER2 cell lines (lower graph) are shown. *Significantly different (P-value < 0.05, Student’s t-test). **Significantly different
(P-value < 0.01, Student’s t-test).
D The plots show the correlation curves between the levels of the indicated RARa-variant transcripts and the RARa protein.
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Figure 9. Effects of RAR agonists on the growth of Luminal and Basal breast cancer cell lines.
The indicated Luminal and Basal cell lines were challenged with increasing concentrations of ATRA, the RARa agonist, AM580, the RARb agonist, UVI2003, and the RARc
agonist, BMS961, for 6 days. The complement of RAR-variant transcripts expressed in each cell line is shown in the left bar graphs (mean  SD of two replicate
measurements). The growth curves (sulforhodamine assay) of the cell lines are illustrated by the right linear plots. The results are expressed in % values relative to the
corresponding control dishes treated with vehicle alone (right graphs). Each result is the mean  SD of five replicate wells. ATRA sc = ATRA score.
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ATRA exerts major quantitative effects on the transcriptomes not
only of Luminal/ER+ tumors, but also of TN cancers (Fig 12A and
Supplementary Table S5). Cluster analysis of the regulated tran-
scripts results in a clear separation between Luminal/ER+ and TN
tumors on the basis of the genomic responses to ATRA. It is interest-
ing to notice that cluster analysis groups together the three Ki67-
unresponsive Luminal/ER+ cases (Patients No. 41, 55 and 61). A
total of 1,702 genes are significantly regulated by ATRA (P < 0.005,
paired t-test) in either TN or Luminal/ER+ tumors. Approximately
20% of the genes (up-regulated genes = 198; down-regulated
genes = 134) are similarly modulated by ATRA in both the
Luminal/ER+ and TN cases (Fig 12B).
We focused our attention on the subset of genes identified as
retinoid targets in various cell types (Balmer & Blomhoff, 2002,
2005; Topletz et al, 2015). Among these 402 genes, 34 are signifi-
cantly up- or down-regulated by ATRA (P < 0.001, paired t-test) in
tissue slices derived from either Luminal/ER+ or TN tumors
(Fig 12C). Five of these genes are differentially regulated in
Luminal/ER+ and TN tumors. The up-regulation of RARRES3 (reti-
noic acid receptor responder 3), TGM2 (transglutaminase 2),
S100A8 (S100 calcium binding protein A8), and CYP26A1 (cyto-
chrome P-450 26A1) is significantly higher in Luminal/ER+ tumors.
In contrast, THBD (thrombomodulin) is significantly up-regulated
only in TN tumors. RARRES3 up-regulation in Luminal/ER+ may
play a role in the anti-motility and anti-metastatic effects of ATRA
(Nwankwo, 2002; Terao et al, 2011), as the factor has been shown
to suppress metastases to the lung in breast cancer (Errico, 2014;
Morales et al, 2014). In contrast, increased induction of CYP26A1
may be detrimental for the anti-tumor action of ATRA, as the
enzyme metabolizes and inactivates the retinoid (Thatcher et al,
2010; Topletz et al, 2012).
To define the biochemical pathways regulated by ATRA and
potentially involved in the anti-tumor action of the retinoid, we
performed gene-network enrichment analysis of the microarray
data, focusing on Luminal/ER+ tumors. Among the top 10
processes enriched (Supplementary Table S6), the ER nuclear signal
transduction pathway is of interest for its role in Luminal breast
cancer growth. For instance, down-regulation of IRS1 and one of
the regulatory subunit of PI3K by ATRA are likely to block the
proliferation of Luminal/ER+ tumors caused by the growth factors
IGF1 and EGF. Out of the 28 types of interactions between couples
of proteins belonging to the ER pathway (Supplementary Table S7),
17 are consistent with an inhibition of the ER pathway by ATRA.
Taken together, the data demonstrate an anti-estrogenic action of
the retinoid in primary tumors, which is in line with what was
reported in breast cancer cell lines (Hua et al, 2009).
We performed an interactome analysis (Fig 12D) looking for
gene products significantly over-connected in the network modu-
lated by ATRA in Luminal/ER+ tumors. We focused on two
groups of genes relevant for the molecular mechanisms underly-
ing the anti-tumor action of ATRA, that is, transcription factors
and kinases (Supplementary Table S8). As for transcription
factors, the list of over-connected genes contains RARA, RARG,
and RXRA. The presence of ESR1 and ESR2 among the top-ranked
transcription factors is in line with the process enrichment analy-
sis described above. Finally, the inclusion of STAT1, STAT5B,
and STAT3 is of relevance given the cross talk between retinoid
receptors and this group of transcription factors in acute myeloid
leukemias (Gianni et al, 1997). As for the kinases, PI3K and AKT
stand out, as ATRA has been shown to inhibit the two corre-
sponding signal transduction pathways in certain breast cancer
cell lines (Paroni et al, 2012).
Discussion
Exploitation of the clinical potential of ATRA requires definition of
the sensitive mammary tumor subtypes and the molecular determi-
nants of this sensitivity. In this study, we examined the responsive-
ness of a large panel of breast cancer cell lines, recapitulating the
heterogeneity of the disease, to the anti-proliferative action of
ATRA. A Luminal phenotype and ER expression are identified as
major determinants of ATRA sensitivity. In contrast, a Basal pheno-
type, which is characteristic of TN tumors, is associated with ATRA
refractoriness. The observations made in cell lines reflect the situa-
tion delineated in primary tumors using short-term tissue-slice
cultures. We propose that ATRA should be used in a neo-adjuvant
or adjuvant setting for the treatment and chemoprevention of
Figure 10. Over-expression of RARa1/3 in ATRA-resistant MDA-MB453 cells and silencing of RARa1/3 in ATRA-sensitive SKBR3 cells.
A RARa1/3 plasmid construct and the corresponding control void vector were stably transfected into ATRA-resistant MDA-MB453 cells. Two cell clones over-expressing
RARa (RARA-C5 and RARA-C7) and two appropriate control clones (Vect-C1 and Vect-C2) were isolated. A RARa3 shRNA plasmid construct and the corresponding void vector
were stably transfected into ATRA-sensitive SKBR3 cells. After selection, two cell clones silenced for RARa3 (RARA-sh18 and RARA-sh19) and two appropriate control
clones (Vect-C6 and Vect-C8) were isolated.
A, D The indicated clones and the parental cell line (WT) were transiently transfected with the RARE-DR5-Luc retinoid reporter construct and the level of luciferase
activity was measured 24 h after treatment with vehicle (DMSO) and ATRA (100 nM), as illustrated in the upper bar graph. Each value is the mean  SD of three
replicate cultures. The levels of the RARa protein measured in the indicated clones by Western blot analysis is shown under the bar graph. To demonstrate that
similar levels of total proteins were loaded in each lane, the b-actin band signal obtained after re-blotting of the gel is shown. FI = Fluorescence intensity.
B, E The panels illustrate the growth curves of the indicated MDA-MB453 and SKBR3 clones and the SKBR3 parental cell lines (WT) measured with the sulforhodamine
assay.
C The bar graphs illustrate the effect of increasing concentrations of ATRA on the growth of the indicated MDA-MB453 clones and the parental cell line. The cell lines
were challenged with vehicle (DMSO) or ATRA for 3, 6, and 9 days prior to the sulforhodamine assay. OD = optical density at 540 nm. Each value is the mean  SD
of five replicate culture wells.
F The graphs illustrate the effect of increasing concentrations of ATRA on the growth of the indicated SKBR3 clones and the parental cell line. The cell lines were
challenged with vehicle (DMSO) or ATRA for 3 and 6 days prior to the sulforhodamine assay. Each value is the mean  SD of five replicate culture wells.
G The panel illustrates the effects exerted by ATRA (0.1 lM) on random cell motility of the indicated MDA-MB453 and SKBR3 clones. The results are representative of
two independent experiments. Each value is the mean  SE of the motility of at least 60 cells.
Data information: * and **, significantly different from the corresponding vehicle-treated control (*P-value < 0.05, **P-value < 0.01, Student’s t-test).
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Luminal ER+ tumors. In ER+ breast cancer, ATRA may represent a
rational addition to anti-estrogens particularly in conditions of
induced resistance to these agents (Belosay et al, 2006; Johansson
et al, 2013). Despite their importance, the Luminal/Basal pheno-
types and ER positivity/negativity are not sufficient determinants of
ATRA sensitivity or resistance. In fact, there is a minority of the
Luminal or ER+ cell lines and tumors which are refractory to the
retinoid and a few Basal cell lines and tumors responding to ATRA.
This indicates that factors other than the cell origin control the
responsiveness of breast cancer cells to this anti-tumor agent.
The results obtained in short-term tissue-slice cultures demon-
strate that ATRA exerts major quantitative effects on the
transcriptomes not only of Luminal/ER+ tumors, but also of TN
cancers. Thus, our transcriptomic data support the concept that the
general refractoriness of TN tumors and the corresponding Basal cell
lines to the anti-proliferative action of ATRA is not associated with a
similar resistance to the transcriptional effects of the retinoid. In
contrast, it is likely that ATRA sensitivity of Luminal/ER+ relative
to TN/Basal tumor cells is the consequence of different transcription
programs activated by the retinoid in the two cell types. The differ-
ent complement of RAR isoforms and splicing variants present in
Luminal/ER+ relative to TN/Basal tumor cells may be at the basis
of these differential responses to ATRA.
The biological activity of ATRA is deemed to be mediated by the
RXR/RAR and RXR/PPARb/d transcription factors via the distinct
cytosolic binding proteins, CRABP2 and FABP5 (Shaw et al, 2003;
Schug et al, 2007; Kannan-Thulasiraman et al, 2010). The correla-
tive results obtained in cell lines and breast tumors indicate that
expression of the RARa3 mRNA and the corresponding protein is
directly associated with ATRA sensitivity, the Luminal phenotype,
and ER positivity. The role of RARa in the anti-proliferative
responses triggered by ATRA is supported by functional studies
involving specific pharmacologic RAR agonists/ antagonists
performed in selected Luminal and Basal cell lines. RARa over-
expression and knockdown experiments provide direct evidence for
the involvement of the receptor not only in ATRA-dependent growth
inhibition, but also in other aspects of ATRA anti-tumor activity. In
addition, RARa is a biomarker of ATRA sensitivity and the major
target for retinoids in breast cancer. This suggests that specific RARa
agonists should be developed for the management of the disease to
avoid side effects and toxicity associated with the clinical use of a
pan-RAR agonist like ATRA (Garattini et al, 2007b, 2014).
Although RARa is an important mediator of ATRA anti-tumor
activity, it is unlikely to represent the only determinant of sensi-
tivity. The search for other genes outside the retinoid pathway
performed in this study resulted in the definition of two gene
sets whose basal expression levels are associated with retinoid
sensitivity/resistance in our panel of cell lines. These gene sets
are relevant from both a basic and an applied perspective. At
the basic level, the two gene sets provide information on previ-
ously unrecognized genes and gene networks which may
control/influence the sensitivity of cancer cells to ATRA. Our
gene sets show a significant overlap (M. Bolis, unpublished
observations) with the gene-expression signatures determined for
PI3K-inhibitors (Daemen et al, 2013). This suggests that part of
the anti-proliferative action of ATRA may involve inhibition of
the PI3K pathway, which is often turned on in breast cancer
cells. The contention is supported by the presence of PI3K
among the over-connected kinases in the network of gene prod-
ucts modulated by ATRA in primary tumors challenged with
ATRA ex vivo. With respect to this, a major link may be repre-
sented by PREX1 (RAC-exchanger-factor-1), an important determi-
nant of the sensitivity of breast cancer cells to PI3K inhibitors
(Ebi et al, 2013). Interestingly, combinations of PI3K inhibitors
and ATRA show additive or synergistic growth effects in selected
breast cancer cell lines (MT, unpublished results). At the applied
level, the two gene sets contain possible pharmacological targets
for the design of therapeutic combinations based on ATRA or
derived retinoids. In addition, these gene sets have the potential
to be optimized in view of their use as diagnostic tools for the
selection of breast cancer patients who may benefit from retinoid-
based treatments.
In conclusion, this work is a first step toward a rational use of
ATRA and derived retinoids in breast cancer. The data obtained
with both the cell lines and the short-term tissue cultures indicate
that ~70% of Luminal breast cancers are likely to be responsive to
ATRA. As ATRA is characterized by low toxicity as well as mild side
effects, our data strongly suggest that the compound is of potential
interest in the adjuvant therapy of the majority of Luminal breast
cancer with particular reference to ER+ tumors. Indeed, the results
obtained represent the rationale for an independent clinical trial (AZ
and EG, personal communication), which we will conduct in
post-menopausal patients suffering from ER+ breast cancer aimed
at evaluating the efficacy of ATRA addition to aromatase inhibitors.
Materials and Methods
Chemicals plasmids and cell lines
The following compounds were used: ATRA (Sigma-Aldrich,
https://www.sigmaaldrich.com), AM580 (Tocris, http://www.
Figure 11. Gene sets associated with ATRA sensitivity.
Using the microarray and RNA-seq data associated with the breast cancer cell lines, two ATRA score-associated gene lists ranked for their variable importance were
generated. Upper Panels: The gene-expression results of the first 100-ranking genes in the RNA-seq (left) and microarray (right) datasets were used to perform a cluster
analysis of the breast cancer cell lines according to the gene-expression profiles. Data are expressed using a log2 scale of the expression signal intensity after normalization
of the data across the different cell lines. The genes marked in red are present in both the microarray and the RNA-seq gene sets. The cell lines marked in red are those
belonging to the ATRA score T1 group and are sensitive to ATRA, while the ones marked in blue belong to the T3 group and are refractory to the retinoid. The left dark blue lines
indicate the genes with higher levels of constitutive expression in the ATRA-sensitive cell lines, while the light blue lines indicate the genes with higher levels of basal
expression in the ATRA-refractory cell lines. Lower Panels: The box plots show the enrichment score (single sample Gene Set Enrichment Analysis, ssGSEA) of the microarray
(left) and RNA-seq (right) gene sets in the TN (patients 9, 22, 23, 31, 50) and Lum (patients 13, 18, 27, 36, 41, 44, 55, 60, 61, 62, 64) tumors cultured in the absence of ATRA for 48 h.
The P-values of the enrichment are indicated.
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Figure 12. ATRA-dependent perturbations of the transcriptome in primary tumors.
Tissue slices corresponding to the indicated patients were treated with vehicle (DMSO) or ATRA (0.1 lM) for 48 h. Whole-genome gene expression studies were performed on
the extracted total RNA using a microarray platform.
A The heat-map shows the genes significantly up- or down-regulated by ATRA (P < 0.005, paired t-test) in either Luminal-A and -B (Lum) or triple-negative (TN) tumors,
and the results are expressed as the log2 ratio observed between the ATRA and vehicle-treated samples.
B A Venn diagram of the genes up- or down-regulated by ATRA in TN and Lum tumors is shown. The number of genes commonly or selectively regulated in TN and Lum
tumors is indicated.
C The heat-map shows the regulation patterns of the retinoid-dependent genes significantly modulated by ATRA (P < 0.001) in either TN or Lum tumors. The symbols
highlighted in red represent the five genes differentially and significantly regulated by ATRA in Lum versus TN tumors.
D The panel shows the estrogen-receptor (ESR1) pathway, which is significantly enriched for genes regulated by ATRA in Lum tumors. The green arrows indicate
up-regulatory or stimulating interactions, while the red arrows indicate down-regulatory or inhibitory interactions. The gray arrows indicate unknown types of
interactions. The red and blue dots above the protein symbols indicate the effect of ATRA in Lum tumors (red = up-regulation; blue = down-regulation).
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tocris.com), BMS961 (Tocris), ER50891 (Tocris), CD2665 (Tocris),
and UVI2003 (a kind gift of Dr. Angel De Lera, Universidade de
Vigo, Spain). Sulforhodamine was from Sigma-Aldrich Co. A list of
the cell lines, their characteristics, and origin is available in Supple-
mentary Table S1. The plasmid constructs used for RARa3 over-
expression in MDA-MB453 cells and knockdown in SKBR3 cells are
described below.
Plasmid construction
To generate the RARa plasmid used for the over-expression in MDA-
MB453 cells, 50 FLAG-tagged RARa1/3 cDNA was introduced into
pcDNA3, using the NdeI and XhoI sites in the multiple cloning region
downstream of the pCMV promoter. To obtain the RARa silencing
construct, a custom-synthesized double-stranded DNA coding for a
RARa-targeting shRNA (50-GATCCGCGGGCACCTCAATGGGTACTT
CCTGTCAGATACCCATTGAGGTGCCCGCTTTTTG-30, the underlined
sequence corresponds to nt 629–646 of the NM_001145301.2
sequence, Sigma-Aldrich) was introduced into the pGreenPuro
plasmid (System Biosciences Inc., http://www.systembio.com),
using the EcoRI and BamHI sites in the multiple cloning region
downstream of the H1 gene promoter. The RARa over-expressing
MDA-MB453 clones and the RARA-silenced SKBR3 clones were
selected, after transfection with Fugene HD (Promega, www.pro-
mega.com), in the presence of 400 lg/ml G418 and 1 lg/ml puro-
mycin (Sigma-Aldrich), respectively.
Short-term tissue slice cultures
Tissue cultures of primary breast tumors were performed as
described (van der Kuip et al, 2006). Briefly, tissue slices (thickness,
200 lm) deriving from surgical specimens of 45 breast cancer
patients who underwent a diagnostic Tru-cut procedure were chal-
lenged with vehicle (DMSO) or ATRA (0.1 lM) for 48 h in
Mammary Epithelial Cell Growth Medium (Lonza, Allendale, NJ).
At the end of the treatment, samples were fixed, paraffin-included,
and dissected into 5-lm slices, which were subjected to immuno-
histochemical staining with an antibody targeting the Ki67 prolifera-
tion-associated marker. The percentage of Ki67-positive tumor cells
in the various samples was assessed in a quantitative manner by
automatic image analysis, and the results are illustrated. Scoring of
Ki67 was blinded as to treatment. Each value represents the
mean  SE of at least five separate fields for each experimental
sample. The fresh primary tumor samples used for the short-term
tissue slice cultures aimed at assessing ATRA sensitivity were
supplied by Fondazione S. Maugeri, Pavia. All the procedures were
approved by the internal ethical committee of the Fondazione
S. Maugeri, and an informed consent for the donation of the sample
was obtained from patients.
ATRA score
Cell lines were exposed to increasing concentrations of ATRA
(0.001–10.0 lM) for 3, 6, and 9 day, and cell growth was deter-
mined with sulforhodamine assays (Skehan et al, 1990; Voigt, 2005;
Vichai & Kirtikara, 2006). A detailed description of the ATRA scores
and associated mathematical equations and models is available in
Supplementary Methods.
Xenotransplants of HCC-1599 cells
HCC-1599 cells (1 × 107/ animal) were injected subcutaneously on
both flanks of female 6-week-old SCID mice weighing ~18 g (Harlan
Laboratories, http://www.harlan.com). All the experiments were
performed following approval of the internal Ethical Committee on
Animal Experimentation and were conducted in compliance with the
Italian legislation. Tumor volume was determined with a caliper and
by magnetic resonance imaging (MRI, Supplementary Methods).
PCR and Western blot analyses
Real-time PCR was performed using Taqman assays (Terao et al,
2011). Amplimers and Taqman probes (Life Technologies Italia,
The paper explained
Problem
All-trans retinoic acid (ATRA) is the primary vitamin A metabolite and
a promising agent in the treatment/chemoprevention of breast cancer.
Breast cancer is very heterogeneous, being a collection of different
diseases. A rational use of ATRA in breast cancer requires the defini-
tion of the sensitive subtypes and the molecular determinants under-
lying retinoid sensitivity.
Results
We examined ATRA sensitivity in a large panel of breast cancer cell
lines, recapitulating the heterogeneity of the disease after develop-
ment of a new parameter (ATRA score) defining ATRA sensitivity in a
quantitative manner. Luminal and ER+ (estrogen-receptor-positive) cell
lines are generally sensitive to ATRA. In contrast, refractoriness or low
sensitivity is associated with a Basal phenotype and HER2 positivity.
The associations between cellular phenotype and ATRA sensitivity are
confirmed using short-term tissue-slice cultures of primary tumors,
which also result in the definition of the modifications in the tran-
scriptome afforded by ATRA in Luminal and Basal tumors. Using a reti-
noid-pathway-oriented approach, RARa is identified as the only
member of the retinoid pathway directly associated with the Luminal
phenotype, estrogen positivity, and ATRA sensitivity. Studies in
selected Luminal and Basal cell lines with RAR-specific agonists/antag-
onists confirm that RARa is the principal mediator of ATRA responsive-
ness. In addition, RARa over-expression sensitizes ATRA-resistant cells
to the retinoid. In contrast, RARa silencing in ATRA-sensitive cells
abrogates the activity of the retinoid. All this is paralleled by similar
effects on ATRA-dependent inhibition of cell motility, indicating that
RARa mediates also ATRA anti-metastatic effects. Whole-genome
gene-expression data allow the definition of two overlapping gene
sets expressed in basal conditions and characterized by predictive
potential and associated with ATRA sensitivity in breast cancer cell
lines and tumors.
Impact
From a basic point of view, we provide information as to the breast
cancer cellular phenotypes and the RAR isoform regulating ATRA
sensitivity. In addition, we identify a first list of genes of functional
relevance for the anti-tumor activity of ATRA and derived retinoids
in breast cancer. From an applied perspective, the study provides
fundamental information for the development of retinoid-based
therapeutic strategies aimed at the stratified treatment of breast
cancer. Finally, the data suggest that therapeutic strategies based
on the use of RARa-specific retinoids may overcome the toxicity
problems associated with the clinical use of a pan-RAR agonist like
ATRA.
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Monza, Italy) are listed in Supplementary Methods. Western blots
were performed with RARa (Gianni et al, 2012), b-actin, tubulin,
SMAD3 (Paroni et al, 2012), and b-catenin (Paroni et al, 2012) anti-
bodies.
Gene-expression studies in short-term tissue cultures of
primary tumors
Tissue slices were incubated with vehicle (DMSO) or ATRA
(0.1 lM) for 48 h. Total RNA was extracted with the miRNeasy Mini
kit (QIAGEN), labeled with the Lowinput Quick Amp labeling kit
(Cy3 mono color, Agilent), and hybridized to whole-genome gene
expression microarrays (Agilent). Fluorescent signals were deter-
mined and quantified with an Agilent microarray laser scanner. The
microarray raw data and experimental protocols were deposited in
the Arrayexpress database (accession No. E-MTAB-3313).
Bioinformatic analysis of the gene-expression microarray and
RNA-seq data
Gene expression data for the cell lines were derived from the
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays (pro-
vided by CCLE, http://www.broadinstitute.org/ccle). RAW
sequencing data (Illumina-paired end reads) were derived from
two distinct datasets. The first dataset is publicly available in the
CCLE project and .BAM files where downloaded through the
cgdownload utility from the Cancer Genomics Hub (CGHub/
UCSC, https://cghub.ucsc.edu). Sequencing data (.FASTQ files)
for those cell lines that were not part of this first set were down-
loaded from a second GenBank dataset under the accession
GSE48216 (GenBank). The heat-maps were generated using the
algorithms available in T-Mev (http://www.tm4.org). Further
details on the bioinformatic analyses performed on all the gene-
expression data are available in the appropriate sections of the
Supplementary Information.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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